Tools
Tools
Gunawardena, Tharusha, Corballis, Natasha, Merinopoulos, Ioannis, Tsampasian, Vasiliki, Reinhold, Johannes 
ORCID: https://orcid.org/0000-0003-2412-2574, Eccleshall, Simon and Vassiliou, Vassilios S. ORCID: https://orcid.org/0000-0002-4005-7752
(2022)
Acute vessel closure or major adverse cardiac events of drug-coated balloons and stents: A systematic review and meta-analysis.
BioMed, 2 (4).
pp. 442-451.
ISSN 2673-8430
Preview |
PDF (biomed-02-00035)
- Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
While the use of drug-eluting stents (DES) has become the first-line strategy for treating coronary artery disease, there are still drawbacks with their use. As our understanding of coronary artery anatomy and physiology evolves, growing evidence supports the use of drug-coated balloons (DCB) not only in the treatment of in-stent restenosis but also in de novo lesions. The aim of this systematic review and meta-analysis is to determine if there is a difference in outcomes when DCBs are used versus when stents are used. PubMed, Cochrane and Web of Science databases were systematically searched. The primary outcome of the meta-analysis was acute vessel closure and the secondary outcomes were stent complications including major adverse cardiovascular events (MACE) and all-cause mortality. Eleven studies with a total of 2349 patients were included. No significant difference was found in terms of acute vessel closure between DCBs and all stents (2.6% vs. 1.0%, OR: 2.13 (0.74–6.44), I2: 4%, p = 0.16). Furthermore, there was no difference in MACE (6.8% vs. 10.1%, OR: 0.53 (0.27–1.04), I2: 48%, p = 0.06), all-cause mortality and target lesion revascularisation. This meta-analysis suggests that the use of DCBs is a safe alternative to stents when treating coronary artery disease.
| Item Type: | Article |
|---|---|
| Additional Information: | Funding information: Natasha Corballis and Vasiliki Tsampasian are NIHR Academic Clinical Fellows. Simon Eccleshall received funding for lectures and proctorship from B Braun, Medtronic and MedAlliance and funding for investigator-initiated research unrelated to this work from B Braun. Johannes Reinhold is an NIHR Senior Clinical Lecturer. Vassiliou receives funding for investigator-initiated research unrelated to this work from B Braun and Medtronic. This work was partially supported by the Norfolk Heart Trust. No direct funding was received for this systematic review and meta-analysis. |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 04 Sep 2023 16:30 |
| Last Modified: | 19 Oct 2023 03:38 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/92986 |
| DOI: | 10.3390/biomed2040035 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |